Absci (NASDAQ:ABSI – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Absci to related businesses based on the strength of its valuation, analyst recommendations, earnings, risk, profitability, institutional ownership and dividends.
Profitability
This table compares Absci and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Absci | -7,756.38% | -61.71% | -54.52% |
| Absci Competitors | -9,046.59% | -199.78% | -30.61% |
Institutional & Insider Ownership
52.0% of Absci shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.5% of Absci shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Absci and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Absci | 1 | 0 | 11 | 0 | 2.83 |
| Absci Competitors | 9789 | 15065 | 45328 | 1572 | 2.54 |
Absci currently has a consensus target price of $14.50, suggesting a potential upside of 43.76%. As a group, “Biotechnology” companies have a potential upside of 95.43%. Given Absci’s rivals higher possible upside, analysts clearly believe Absci has less favorable growth aspects than its rivals.
Volatility and Risk
Absci has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, Absci’s rivals have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.
Valuation & Earnings
This table compares Absci and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Absci | $2.80 million | -$115.18 million | -12.61 |
| Absci Competitors | $691.14 million | $10.43 million | -10.08 |
Absci’s rivals have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
Absci rivals beat Absci on 7 of the 13 factors compared.
About Absci
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Absci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Absci and related companies with MarketBeat.com's FREE daily email newsletter.
